Table 4.

Effects of CaP supplementation on blood lipids.

Parameter	Placebo	CaP	Change
Total cholesterol	4.80 ± 1.06	4.65 * ± 1.03	−0.15 ± 0.47
(mmol/L)	(4.6–5.0)	(4.4–4.9)	(−0.25–(−0.04))
HDL-cholesterol	1.45 ± 0.37	1.48 ± 0.38	0.03 ± 0.17
(mmol/L)	(1.4–1.5)	(1.4–1.6)	(−0.01–0.07)
LDL-cholesterol	2.87 ± 0.94	2.76 * ± 0.92	−0.11 # ± 0.42
(mmol/L)	(2.7–3.1)	(2.6–3.0)	(−0.2–(−0.02))
LDL:HDL-ratio	2.12 ± 0.91	1.99 * ± 0.84	−0.13 ± 0.41
	(1.9–2.3)	(1.8–2.2)	(−0.2–(−0.04))
Triacylglycerides	0.99 ± 0.59	0.96 ± 0.37	−0.03 ± 0.54
(mmol/L)	(0.9–1.1)	(0.9–1.0)	(−0.2–0.1)

n (studies) = 3; n (subjects) = 81; mean ± standard deviation; (95% confidence interval); CaP three–four weeks’ intervention with Ca₅(PO₄)₃OH (pentacalcium hydroxy-trisphosphate); * significantly different to placebo (paired Student’s t-test, p ≤ 0.05); ^# significantly different to zero (one-way ANOVA, p ≤ 0.05).